Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 19, Issue 11, 2017, Pages 1521-1528

  Guzman, Cristina B ^a   Zhang, Xiaotian M ^a   Liu, Rong ^a   Regev, Arie ^a   Shankar, Sudha ^a   Garhyan, Parag ^a   Pillai, Sreekumar G ^a   Kazda, Christof ^a   Chalasani, Naga ^b   Hardy, Thomas A ^a  

^a ELI LILLY AND COMPANY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

fatty liver; glucagon antagonist; randomized trial; type 2 diabetes

Indexed keywords

ADOMEGLIVANT; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; PLACEBO; SITAGLIPTIN; BIPHENYL DERIVATIVE; GLUCAGON RECEPTOR;

ADULT; AGED; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FATTY LIVER; FEMALE; GLUCOSE BLOOD LEVEL; HEPATIC FAT FRACTION; HEPATOBILIARY PARAMETERS; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SYSTOLIC BLOOD PRESSURE; WEIGHT GAIN; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; LIPID METABOLISM; LIVER; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; BIPHENYL COMPOUNDS; DIABETES MELLITUS, TYPE 2; FATTY LIVER; FEMALE; HUMANS; HYPOGLYCEMIA; LIPID METABOLISM; LIVER; MALE; MIDDLE AGED; RECEPTORS, GLUCAGON;

EID: 85020314055     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12958     Document Type: Article

References (26)

1. Ahrén B. Glucagon—early breakthroughs and recent discoveries. Peptides. 2015;67:74-81.
2. Jazayeri A, Doré AS, Lamb D, et al. Extra-helical binding site of a glucagon receptor antagonist. Nature. 2016;533(7602):274-277.
3. Bagger JI, Knop FK, Holst JJ, Vilsbøll T. Glucagon antagonism as a potential therapeutic target in type 2 diabetes. Diabetes Obes Metab. 2011;13(11):965-971.
4. Unger RH, Orci L. Glucagon and the A cell: physiology and pathophysiology (first two parts). N Engl J Med. 1981;304(25):1518-1524.
5. Longuet C, Sinclair EM, Maida A, et al. The glucagon receptor is required for the adaptive metabolic response to fasting. Cell Metab. 2008;8(5):359-371.
6. Kazda CM, Ding Y, Kelly RP, et al. Evaluation of efficacy and safety of the glucagon receptor antagonist LY2409021 in patients with type 2 diabetes: 12- and 24-week phase 2 Studies. Diabetes Care. 2016;39(7):1241-1249.
7. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15(7):539-553.
8. Kazda CM, Frias J, Foga I, et al. Treatment with the glucagon receptor antagonist LY2409021 increases ambulatory blood pressure in patients with type 2 diabetes. Diabetes Obes Metab. 2017;19(8):1071–1077.
9. Sloan JH, Siegel RW, Ivanova-Cox YT, Watson DE, Deeg MA, Konrad RJ. A novel high-sensitivity electrochemiluminescence (ECL) sandwich immunoassay for the specific quantitative measurement of plasma glucagon. Clin Biochem. 2012;45(18):1640-1644.
10. Guiu B, Loffroy R, Petit JM, et al. Mapping of liver fat with triple-echo gradient echo imaging: validation against 3.0-T proton MR spectroscopy. Eur Radiol. 2009;19(7):1786-1793.
11. Firneisz G. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age? World J Gastroenterol. 2014;20(27):9072-9089.
12. Sammons MF, Lee EC. Recent progress in the development of small-molecule glucagon receptor antagonists. Bioorg Med Chem Lett. 2015;25(19):4057-4064.
13. Ali S, Drucker DJ. Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes. Am J Physiol Endocrinol Metab. 2009;296(3):E415-E421.
14. Morgan E, Smith A, Watts L, et al. ISIS-GCGRRX, an antisense glucagon receptor antagonist, caused rapid, robust, and sustained improvements in glycemic control without changes in BW, BP, lipids, or hypoglycemia in T2DM patients on stable metformin therapy [Abstract 109-LB]. Diabetes. 2014;63(suppl 1A):LB28.
15. Vajda EG, Logan D, Lasseter K, et al. Pharmacokinetics and pharmacodynamics of the glucagon receptor antagonist LGD-6972 in a multi-dose clinical trial [Abstract 1193-P]. Diabetes. 2015;64(suppl 1):A308.
16. Bergman A, Tan B, Somayaji V, Calle RA, Kazierad DJ. Assessment of PF-06291874 (PF), a glucagon receptor antagonist administered as monotherapy for four weeks in patients with type 2 diabetes mellitus (T2DM) [Abstract 1084-P]. Diabetes. 2016;65(suppl 1):A283.
17. Gumbiner B, Esteves B, Dell V, et al. Robust glucose and A1c lowering after a single dose of RN909 (PF-06293620) in Type 2 diabetes (T2D) [Abstract 110-LB]. Diabetes. 2016;65(suppl 1):LB30.
18. Business Wire. REMD biotherapeutics phase 2 clinical study of REMD-477 for patients with type 2 diabetes now enrolling. Published November 19, 2015. http://www.businesswire.com/news/home/20151119006082/en/REMD-Biotherapeutics-Phase-2-Clinical-Study-REMD-477. Accessed August 12, 2016.
19. Pearson MJ, Unger RH, Holland WL. Clinical trials, triumphs, and tribulations of glucagon receptor antagonists. Diabetes Care. 2016;39(7):1075-1077.
20. Engel SS, Xu L, Andryuk PJ, et al. Efficacy and tolerability of MK-0893, a glucagon receptor antagonist (GRA), in patients with type 2 diabetes (T2DM) [Abstract 309-OR]. Diabetes. 2011;60(suppl 1):A85.
21. Ruddy M, Pramanik B, Lunceford J, et al. Inhibition of glucagon-induced hyperglycemia predicts glucose lowering efficacy of a glucagon receptor antagonist, MK-0893, in type 2 diabetes (T2DM) [Abstract 311-OR]. Diabetes. 2011;60(suppl 1):A85-A86.
22. Kelly RP, Garhyan P, Reynolds VL, et al. Glucagon receptor antibody LY2786890 reduced glucose levels in type 2 diabetes mellitus patients [Abstract 106-LB]. Diabetes. 2015;64(suppl 1A):LB27.
23. Christensen M, Bagger JI, Vilsbøll T, Knop FK. The alpha-cell as target for type 2 diabetes therapy. Rev Diabet Stud. 2011;8(3):369-381.
24. Tolman KG, Fonseca V, Dalpiaz A, Tan MH. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care. 2007;30(3):734-743.
25. Amacher DE, Chalasani N. Drug-induced hepatic steatosis. Semin Liver Dis. 2014;34(2):205-214.
26. Patel V, Sanyal AJ. Drug-induced steatohepatitis. Clin Liver Dis. 2013;17(4):533-546.